Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Stallard

Showing results (61-70 of 153) with videos related to

Pageof 16
Sort By:
Statistics in Medicine|August 21, 2024
Group sequential designs for clinical trials when the maximum sample size is uncertainAmin Yarahmadi, Lori E Dodd, Thomas Jaki, et al.
Pharmaceutical Statistics|May 3, 2014
Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome dataCornelia Ursula Kunz, Tim Friede, Nick Parsons, et al.
Statistics in Medicine|December 10, 2025
Group-Sequential Designs With an Externally-Driven Change of Primary EndpointAmin Yarahmadi, Lori E Dodd, Peter Horby, et al.
Biometrical Journal. Biometrische Zeitschrift|November 26, 2016
Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptationsCornelia U Kunz, Nigel Stallard, Nicholas Parsons, et al.
Spine|February 1, 2014
Evaluating the quality of subgroup analyses in randomized controlled trials of therapist-delivered interventions for nonspecific low back pain: a systematic reviewDipesh Mistry, Shilpa Patel, Siew Wan Hee, et al.
Spine|May 9, 2015
Can we convert between outcome measures of disability for chronic low back pain?Tom Morris, Siew Wan Hee, Nigel Stallard, et al.
Statistics in Medicine|June 27, 2015
Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trialNigel Stallard, Cornelia Ursula Kunz, Susan Todd, et al.
Journal of Biopharmaceutical Statistics|April 5, 2014
A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpointsCornelia Ursula Kunz, Tim Friede, Nicholas Parsons, et al.
Trials|March 11, 2021
Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveatsKim May Lee, Louise C Brown, Thomas Jaki, et al.
Pharmaceutical Statistics|December 17, 2008
Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programmeJohn Whitehead, Patrick Kelly, Yinghui Zhou, et al.
Pageof 16

Showing results (61-70 of 153) with videos related to

Sort By:
Pageof 16
Statistics in Medicine|August 21, 2024
Group sequential designs for clinical trials when the maximum sample size is uncertainAmin Yarahmadi, Lori E Dodd, Thomas Jaki, et al.
Pharmaceutical Statistics|May 3, 2014
Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome dataCornelia Ursula Kunz, Tim Friede, Nick Parsons, et al.
Statistics in Medicine|December 10, 2025
Group-Sequential Designs With an Externally-Driven Change of Primary EndpointAmin Yarahmadi, Lori E Dodd, Peter Horby, et al.
Biometrical Journal. Biometrische Zeitschrift|November 26, 2016
Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptationsCornelia U Kunz, Nigel Stallard, Nicholas Parsons, et al.
Spine|February 1, 2014
Evaluating the quality of subgroup analyses in randomized controlled trials of therapist-delivered interventions for nonspecific low back pain: a systematic reviewDipesh Mistry, Shilpa Patel, Siew Wan Hee, et al.
Spine|May 9, 2015
Can we convert between outcome measures of disability for chronic low back pain?Tom Morris, Siew Wan Hee, Nigel Stallard, et al.
Statistics in Medicine|June 27, 2015
Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trialNigel Stallard, Cornelia Ursula Kunz, Susan Todd, et al.
Journal of Biopharmaceutical Statistics|April 5, 2014
A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpointsCornelia Ursula Kunz, Tim Friede, Nicholas Parsons, et al.
Trials|March 11, 2021
Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveatsKim May Lee, Louise C Brown, Thomas Jaki, et al.
Pharmaceutical Statistics|December 17, 2008
Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programmeJohn Whitehead, Patrick Kelly, Yinghui Zhou, et al.
Pageof 16